^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jiataile (sacituzumab tirumotecan)

    i
    Other names: SKB-264, MK2870, MK 2870, MK-2870, SKB 264, SKB264, sac-TMT
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    1d
    OptiTROP Breast02: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    1d
    Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov)
    P2, N=35, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Jul 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 negative
    |
    Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab) • Simponi (golimumab)
    2d
    Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date
    |
    Jiataile (sacituzumab tirumotecan)
    6d
    The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability. (PubMed, Explor Target Antitumor Ther)
    While third-generation tyrosine kinase inhibitors (TKIs) like osimertinib have long served as the frontline standard, the emergence of heterogeneous resistance mechanisms requires more robust therapeutic strategies. This review evaluates the clinical impact of the MARIPOSA trial, which demonstrated the superior efficacy of combining the bispecific antibody amivantamab with lazertinib...Furthermore, we explore the diversifying landscape of second-line interventions, including the rise of antibody-drug conjugates (ADCs) like Sac-TMT and patritumab-deruxtecan, dual PD-1/VEGF inhibitors, and novel fourth-generation TKIs. By integrating preclinical insights on drug-tolerant persister cells with late-phase clinical data, this article outlines a future for EGFR-mutant NSCLC management defined by precision sequencing and the proactive mitigation of molecular resistance.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • patritumab deruxtecan (U3-1402) • Lazcluze (lazertinib) • Jiataile (sacituzumab tirumotecan)
    9d
    Sacituzumab Tirumotecan for Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan)
    9d
    Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Jiataile (sacituzumab tirumotecan)
    10d
    A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) (2023-508047-40-00)
    P2/3, N=283, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
    12d
    Trofuse-023: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (clinicaltrials.gov)
    P3, N=851, Recruiting, Merck Sharp & Dohme LLC | N=301 --> 851
    Enrollment change
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • Jiataile (sacituzumab tirumotecan)
    13d
    A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) (2024-520014-22-00)
    P2/3, N=265, Recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    paclitaxel • docetaxel • Jiataile (sacituzumab tirumotecan) • Javlor (vinflunine)
    17d
    TROP-LUNG: A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy (clinicaltrials.gov)
    P2, N=25, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Ivesa (firmonertinib) • Jiataile (sacituzumab tirumotecan)
    17d
    Sacituzumab Tirumotecan in Combination with Anlotinib in Previously Treated Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Prospective, Single-Arm, Phase II Study (ChiCTR2600120856)
    P2, N=33, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    17d
    A single-arm, multicenter, phase II study of sacituzumab tirumotecan combined with tagitanlimab for the treatment of advanced non-small cell lung cancer that has progressed after previous platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy (ChiCTR2600119570)
    P2, N=42, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)